329 related articles for article (PubMed ID: 27311966)
1. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
2. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
[TBL] [Abstract][Full Text] [Related]
3. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
Epstein L; See I; Edwards JR; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
[TBL] [Abstract][Full Text] [Related]
4. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
[TBL] [Abstract][Full Text] [Related]
5. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
[TBL] [Abstract][Full Text] [Related]
6. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
[TBL] [Abstract][Full Text] [Related]
7. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
Balian C; Garcia M; Ward J
J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
[TBL] [Abstract][Full Text] [Related]
9. Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH;
Pediatr Blood Cancer; 2020 Aug; 67(8):e28234. PubMed ID: 32386095
[TBL] [Abstract][Full Text] [Related]
10. Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy.
de Mooij CEM; van der Velden WJFM; de Haan AFJ; Fazel S; van Groningen LFJ; Blijlevens NMA
Bone Marrow Transplant; 2022 Sep; 57(9):1373-1381. PubMed ID: 35661156
[TBL] [Abstract][Full Text] [Related]
11. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
[TBL] [Abstract][Full Text] [Related]
12. Impact of removing mucosal barrier injury laboratory-confirmed bloodstream infections from central line-associated bloodstream infection rates in the National Healthcare Safety Network, 2014.
See I; Soe MM; Epstein L; Edwards JR; Magill SS; Thompson ND
Am J Infect Control; 2017 Mar; 45(3):321-323. PubMed ID: 27856070
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Best Practice Prevention Bundle on Central Line-associated Bloodstream Infection (CLABSI) Rates and Outcomes in Pediatric Hematology, Oncology, and Hematopoietic Cell Transplantation Patients in Inpatient and Ambulatory Settings.
Ardura MI; Bibart MJ; Mayer LC; Guinipero T; Stanek J; Olshefski RS; Auletta JJ
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e64-e72. PubMed ID: 32960848
[TBL] [Abstract][Full Text] [Related]
14. Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.
Giri VK; Kegerreis KG; Ren Y; Bohannon LM; Lobaugh-Jin E; Messina JA; Matthews A; Mowery YM; Sito E; Lassiter M; Saullo JL; Jung SH; Ma L; Greenberg M; Andermann TM; van den Brink MRM; Peled JU; Gomes ALC; Choi T; Gasparetto CJ; Horwitz ME; Long GD; Lopez RD; Rizzieri DA; Sarantopoulos S; Chao NJ; Allen DH; Sung AD
Transplant Cell Ther; 2021 Mar; 27(3):262.e1-262.e11. PubMed ID: 33781532
[TBL] [Abstract][Full Text] [Related]
15. Defining Incidence and Risk Factors for Catheter-Associated Bloodstream Infections in an Outpatient Adult Hematopoietic Cell Transplantation Program.
McDonald MK; Culos KA; Gatwood KS; Prow C; Chen H; Savani BN; Byrne M; Kassim AA; Engelhardt BG; Jagasia M; Satyanarayana G
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2081-2087. PubMed ID: 29753159
[TBL] [Abstract][Full Text] [Related]
16. Association between parenteral nutrition-containing intravenous lipid emulsion and bloodstream infections in patients with single-lumen central venous access: A secondary analysis of a randomized trial.
Gavin NC; Larsen E; Runnegar N; Mihala G; Keogh S; McMillan D; Ray-Barruel G; Rickard CM
JPEN J Parenter Enteral Nutr; 2023 Aug; 47(6):783-795. PubMed ID: 37288612
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Bloodstream Infections after Hematopoietic Stem Cell Transplantation for Hurler Syndrome.
Dunseath C; O'Connor G; Mahulkar S; Badia P; Koo J; Dandoy CE
Transplant Cell Ther; 2023 Nov; 29(11):707.e1-707.e4. PubMed ID: 37582469
[TBL] [Abstract][Full Text] [Related]
18. Applying mucosal barrier injury laboratory-confirmed bloodstream infection criteria in patients with solid tumors and hematologic malignancies: A retrospective cohort study looking for the real source of infection.
Puin da Silva AC; Vieira MF; Freire MP; Vaz L; Bonazzi PR; Ibrahim KY; Diz MDPE; Hoff PM; Pereira J; Rocha VG; Abdala E
Infect Control Hosp Epidemiol; 2023 Feb; 44(2):302-304. PubMed ID: 35144717
[TBL] [Abstract][Full Text] [Related]
19. Bloodstream and central line isolates from hematopoietic stem cell transplant recipients: data from a developing country.
Ali N; Adil SN; Shaikh MU
Transpl Infect Dis; 2014 Feb; 16(1):98-105. PubMed ID: 24383473
[TBL] [Abstract][Full Text] [Related]
20. Central line-associated bloodstream infections in neonates with gastrointestinal conditions: developing a candidate definition for mucosal barrier injury bloodstream infections.
Coffin SE; Klieger SB; Duggan C; Huskins WC; Milstone AM; Potter-Bynoe G; Raphael B; Sandora TJ; Song X; Zerr DM; Lee GM;
Infect Control Hosp Epidemiol; 2014 Nov; 35(11):1391-9. PubMed ID: 25333434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
